Offer ends in:

Are you a High Risk Appetite Investor ?

Bringing to you Some High-Octane ‘Under 20 Cents’ Stocks!

Market Beating Performance Since Inception


Note: S&P/ASX Small Ordinaries serves as a benchmark for the comparison. Relative Performance since 31st July 2020 Rebased to 100; Data from ASX, Refinitiv, Kalkine (*31 July 2020 to 29 October 2020)

Some Winners from Our ‘Stocks Under 20 Cents’ Portfolio*

8COMMON LIMITED
(ASX: 8CO)
Software & Tech
Services
84.62%
since recommendation
Botanix Pharmaceuticals Ltd (ASX: BOT) Cannabinoid Pharmaceutical
Company
79.63%
since recommendation
Arafura Resources Limited(ASX: ARU) Mineral Exploration
Company
41.43%
since recommendation
Oncosil Medical Ltd
(ASX: OSL)
Medical Technology
Company
28.57%
since recommendation

*Gains have been estimated using average buy values in view of multiple recommendations given over time. The same also take into account dividends over the length of coverage. Past performance is neither an indicator nor a guarantee of future performance.

Why S&P/ASX Small Ordinaries Space Holds Some Importance?

S&P/ASX Small Ordinaries outperformed S&P/ASX 200 price returns by +6.6% YTD


  • S&P ASX Small Ordinaries plummeted 41% versus 36% fall in S&P/ASX 200 since the
    peak in Feb’2020
  • Impressive recovery of ~52% in S&P/ASX Small Ordinaries since March’ 2020 lows versus
    31% recovery in S&P/ASX 200 Index
Data Source: ASX, Constructed by Kalkine (as at the close of 29th October 2020); Relative Performance since
2nd January 2020 Rebased to 100

Stocks under 20 cents

For $69 For $39  

I hereby agree and consent to the terms and conditions & privacy policy.
  • Kalkine’s ‘Stocks Under 20 cents’ report can offer access to high growth small-caps (less than $300 million market capitalization) with potential to generate alpha returns
  • Remember, Investment during early stages of a company’s growth can sometimes yield tremendous rewards
  • It is also important to conduct extensive due diligence as associated risk(s) is also higher for such stocks
  • Avail advantages from market disruption
  • We aim to cover businesses with improving balance sheets and ROE while highlighting the proportionate level of risks to be looked at

Risk-Reward Trade-off for Small-Cap Investors

  • Investors should be wary of the velocity and gravity of stock market correction for small-cap stocks as panic sweeps in during uncertain times
  • Highly leveraged businesses with discretionary revenue sources may be more prone to volatility
  • Small businesses carry higher risk(s) versus well-established large-cap and mid-cap companies
  • Systematic or unsystematic risks need to be analyzed in a comprehensive manner to minimize the uncertainty around stocks

Thousands of Loyal Members

Contact us

  • Suite 202, 234 George Street, Sydney, New South Wales, Australia. 2000

  • Toll Free No: 1800-272-662
    (02) 9042 2324, (02) 9042 2353, (61) 29159 2555


ABN: 34 154 808 312 ACN: 154 808 312 Copyright 2021 Kalkine Pty Ltd. All rights reserved.
Kalkine Australia
Kalkine UK
Kalkine New Zealand
Kalkine canada

Disclaimer - Kalkine Pty Ltd (ABN 34 154 808 312) holds Australian Financial Services Licence (425376). Kalkine is authorised to provide general advice only. The information on https://www.kalkine.com.au/ does not take into account any of your investment objectives, financial situation or needs. Before you make a decision about whether to acquire a financial product, you should obtain the Product Disclosure Statement from the product issuer. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions.